Less than a year after cutting roughly 30% of its employees, BioAtla is letting go of an even larger chunk of its workforce as it considers its future, which could include strategic partnerships and selling off assets.

Original title: “BioAtla Axes 70% of Staff, Explores Strategic Options”

Cure Rare Disease (CRD), a non-profit biotechnology organization, today announced a landmark partnership with the LGMD2L Foundation. This collaboration is ba... “This partnership with the LGMD2L Foundation is a testament to the power of collaboration between drug development organizations and advocacy groups in the fight against rare diseases,” said Rich Horgan, CEO of Cure Rare Disease. “This significant funding allows us to deploy our drug development engine to accelerate a promising gene therapy for the LGMD2L community. We are deeply grateful for the LGMD2L Foundation's trust and commitment as we work together to bring a treatment to patients living with LGMD2L and their families.” CRD is committed to accelerating the development of treatments for individuals with rare diseases through a patient-centric approach to research and development. The company's programs include gene therapy and antisense oligonucleotide (ASO) treatments for a range of rare diseases. For more information, visit www.cureraredisease.org. ... The LGMD2L Foundation was established in 2018 to unite people afflicted by this rare disease, raise awareness, and provide a forum to connect, discuss, and build community. “Gene therapy is the most promising therapeutic avenue for this devastating disease, yet no private-sector programs are currently advancing this approach,” said Hal Tily, VP Research for the LGMD2L Foundation. “This partnership marks a pivotal moment for patient-led organizations in shaping their own futures. CRD’s track record navigating the complexities of therapeutic development gives us strong confidence that this investment can change the lives of individuals and families affected by LGMD2L.” · This effort underscores a shared mission to streamline the development of treatments for rare diseases often overlooked by traditional pharmaceutical pipelines, and highlights how committed organizations can come together to make meaningful progress for their communities. WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $7.4 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of a novel gene therapy for Limb-Girdle Muscular Dystrophy Type 2i/R9 (LGMD2i/R9), a progressive neuromuscular disorder with limited treatment options. Cure Rare Disease launched its LGMD2i/R9 program to develop a therapeutic solution for patients suffering from this rare condition.

Original title: “Cure Rare Disease and LGMD2L Foundation Announce Multi-Year Partnership to Develop Gene Therapy for Anoctamin 5-Related Disease”

“This partnership with the LGMD2L ... and advocacy groups in the fight against rare diseases,” said Rich Horgan, CEO of Cure Rare Disease. “This significant funding allows us to deploy our drug development engine to accelerate a promising gene therapy for the LGMD2L community. We are deeply grateful for the LGMD2L Foundation's trust and commitment as we work together to bring a treatment to patients living with ... “This partnership with the LGMD2L Foundation is a testament to the power of collaboration between drug development organizations and advocacy groups in the fight against rare diseases,” said Rich Horgan, CEO of Cure Rare Disease. “This significant funding allows us to deploy our drug development engine to accelerate a promising gene therapy for the LGMD2L community. We are deeply grateful for the LGMD2L Foundation's trust and commitment as we work together to bring a treatment to patients living with LGMD2L and their families.” CRD is committed to accelerating the development of treatments for individuals with rare diseases through a patient-centric approach to research and development. The company's programs include gene therapy and antisense oligonucleotide (ASO) treatments for a range of rare diseases. For more information, visit www.cureraredisease.org. ... The LGMD2L Foundation was established in 2018 to unite people afflicted by this rare disease, raise awareness, and provide a forum to connect, discuss, and build community. “Gene therapy is the most promising therapeutic avenue for this devastating disease, yet no private-sector programs are currently advancing this approach,” said Hal Tily, VP Research for the LGMD2L Foundation. “This partnership marks a pivotal moment for patient-led organizations in shaping their own futures. CRD’s track record navigating the complexities of therapeutic development gives us strong confidence that this investment can change the lives of individuals and families affected by LGMD2L.” · This effort underscores a shared mission to streamline the development of treatments for rare diseases often overlooked by traditional pharmaceutical pipelines, and highlights how committed organizations can come together to make meaningful progress for their communities. For more information, visit www.lgmd2l-foundation.org. ... Limb Girdle Muscular Dystrophy type 2L or R12 is a rare genetic disorder that causes progressive muscle weakness. It primarily affects the muscles around the shoulders, upper arms, and thighs, known as the limb girdle muscles. These muscles play a key role in basic activities like walking, lifting, and standing. As the disease progresses, healthy muscle tissue degenerates and is replaced by non-functional tissue, such as fat and scar tissue.

Original title: “Cure Rare Disease and LGMD2L Foundation Announce Multi-Year Partnership to Develop Gene Therapy for Anoctamin 5-Related Disease | Morningstar”

Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly formed company.

Original title: “Candid, in a reverse merger with RallyBio, to go public”

In 2025, Allen launched "Race for ... for CTD treatments to get something into clinical trials. "We just announced that we are funding two, one out of Stanford, one out of Johns Hopkins," Allen said. "Purdue's doing some great work. Some places in Canada and Italy are doing great work to do kind of drug repurposing and drug discovery. So there's things happening." "These children have this rare, very rare disease," ... In 2025, Allen launched "Race for a Cure," asking institutions to put forward their best plans for CTD treatments to get something into clinical trials. "We just announced that we are funding two, one out of Stanford, one out of Johns Hopkins," Allen said. "Purdue's doing some great work. Some places in Canada and Italy are doing great work to do kind of drug repurposing and drug discovery. So there's things happening." "These children have this rare, very rare disease," Dr. "Beast Games" winner Jeff Allen hopes finding a cure for his son's rare disease will unlock new treatments for other brain conditions. He said a potential treatment for CTD could also unlock a new path for treatment for people with Alzheimer's disease or Parkinson's disease. "Our work has always been in cognitive decline in brain aging," he said. "But the hypothesis is, children like Lucas, who have these very rare, focused deficits, unveil points of vulnerability in the human brain that we hypothesize contribute to much more prevalent brain diseases that occur at the other end of life. If we are successful in developing a therapy that could work for Lucas, we perhaps also would be successful in developing a therapy that might be beneficial for older individuals trying to preserve brain function." "This year we're carrying the weight of Lucas on our back, and it signifies the weight that not only Lucas carries every day with CTD, but the weight that families carry. Our aim is to elevate rare diseases, but also to raise money for research. "It's really hard to know that if we find a treatment for CTD, it probably isn't going to help Lucas as much as [it's] going to help a kid who's going to be born in 2030," he said.

Original title: “'Beast Games' winner Jeff Allen hopes finding a cure for his son's rare disease will unlock new treatments for other brain conditions”

As Novo Nordisk continues to lose ground in the obesity market to rival Eli Lilly, the Danish company has started construction projects to establish the ex-Alkermes plant as a hub for supplying oral GLP-1 products to global markets.

Original title: “Novo Commits $506M To Repurpose Irish Plant for Oral Wegovy Production”

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

Original title: “Generate Arrives on Nasdaq Ready To Finally Show the World AI-Powered Medicines”

Reduce risk, cut costs and scale smarter by closing open steps in cell therapy manufacturing.

Original title: “Why it’s critical to close open steps in cell therapy manufacturing”

Generate’s performance came on a day in which the broader financial markets plummeted on news of a higher-than-expected increase during January in the “core” producer price index (PPI) which excludes food and energy prices. Generate carried out the largest biotech IPO so far this year, saying that proceeds from the offering will be used toward clinical trials, as well as platform and pipeline R&D efforts. [Nasdaq] Generate:Biomedicines aims to build on pipeline now focused on cancer, I&I candidates, with plans to use proceeds toward funding clinical trials, platform and therapy R&D GEN – Genetic Engineering and Biotechnology News ... [Front row, center:] Generate: Biomedicines CEO Michael Nally and Jason Silvers, MD, JD, president and chief financial officer, lead a team of employees in celebrating the artificial intelligence (AI)-based platform and drug developer’s $400 million initial public offering (IPO) Friday on the Nasdaq Global Market. Generate:Biomedicines (NASDAQ: GENB), the drug developer focused on creating immunology and inflammation (I&I) and oncology treatments through its own artificial intelligence (AI)-based platform, has launched the year’s largest biotech initial public offering (IPO) to date, raising $400 million in gross proceeds toward clinical trials, as well as platform and pipeline R&D efforts. Among the next two highest biotech IPOs, late-stage oncology and neuroscience drug developer Eikon Therapeutics (NASDAQ: EIKN) raised $381 million gross proceeds priced on February 4, while radiopharma drug developer Aktis Oncology (NASDAQ: AKTS) racked up $318 million in gross proceeds priced on January 8.

Original title: “StockWatch: AI Drug Developer Generates $400M IPO”

Biotech company Generate Biomedicines priced its U.S. IPO at $16 per share, raising $400 million and set to list on Nasdaq under GENB. Led by Flagship Pioneering, the company's lead candidate GB-0895 targets severe asthma and its AI-driven drug discovery approach boosts its growth prospects ... Biotech company Generate Biomedicines priced its U.S. IPO at $16 per share, raising $400 million and set to list on Nasdaq under GENB. Led by Flagship Pioneering, the company's lead candidate GB-0895 targets severe asthma and its AI-driven drug discovery approach boosts its growth prospects amid market volatility. The offering comes as ‌the IPO ⁠market ⁠remains volatile, with swings in high-growth technology stocks driven ​by concerns that artificial intelligence could disrupt established businesses and industries. Bengaluru: Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering comes as ‌the IPO ⁠market ⁠remains volatile, with swings in high-growth technology stocks driven by concerns that artificial intelligence could disrupt established businesses and industries. Recent ​sell-offs have delayed IPO plans of several firms, with analysts noting that successful listings generally depend ​on strong investor sentiment.

Original title: “Generate Biomedicines Raises $400 Million in U.S. IPO, Debuts GENB on Nasdaq, ETPharma”

This collaboration is backed by ... therapy for Anoctamin 5 (ANO5)-related disease, a rare genetic disorder. The transformational partnership will fund a comprehensive, multi-year program dedicated to advancing a potential treatment from initial design to clinical trial ... This collaboration is backed by a generous commitment of $7.65 million from the LGMD2L Foundation to develop a novel gene replacement therapy for Anoctamin 5 (ANO5)-related disease, a rare genetic disorder. The transformational partnership will fund a comprehensive, multi-year program dedicated to advancing a potential treatment from initial design to clinical trial readiness. WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a non-profit biotechnology organization, today announced a landmark partnership with the LGMD2L Foundation. This collaboration is backed by a generous commitment of $7.65 million from the LGMD2L Foundation to develop a novel gene replacement therapy for An... The funding will support a series of critical milestones, including therapeutic design, preclinical studies, manufacturing scale-up, and ultimately a first-in-human clinical trial. This strategic alliance represents a significant step forward in addressing the unmet needs of patients with ANO5-related diseases. In addition to the gene replacement therapy for Anoctamin 5 (ANO5)-related disease, Cure Rare Disease's pipeline includes the development of two gene replacement therapeutics for LGMD2i/R9 and LGMD2g/R7, among therapies for other neuromuscular and neurodegenerative diseases. CRD’s track record navigating the complexities of therapeutic development gives us strong confidence that this investment can change the lives of individuals and families affected by LGMD2L.” · This effort underscores a shared mission to streamline the development of treatments for rare diseases often overlooked by traditional pharmaceutical pipelines, and highlights how committed organizations can come together to make meaningful progress for their communities.

Original title: “Cure Rare Disease and LGMD2L Foundation Announce Multi-Year Partnership to Develop Gene Therapy for Anoctamin 5-Related Disease - PharmiWeb.com”

New Delhi, March 1 (IANS) The developer of Covid-19 vaccine Covaxin, Bharat Biotech is considering an initial public offering that could raise over $500 million, according to sources cited by multiple reports. Discussions are underway including key aspects of the proposed share sale, including ... New Delhi, March 1 (IANS) The developer of Covid-19 vaccine Covaxin, Bharat Biotech is considering an initial public offering that could raise over $500 million, according to sources cited by multiple reports. Discussions are underway including key aspects of the proposed share sale, including size and timing, they said.Bharat Biotech plans Rs 200–250 crore of capital... This included three IPOs worth $428 million and one QIP worth $88 million, the report said. Excluding public market activity, private deals accounted for $3 billion across 68 transactions, marking a sharp rebound in investor appetite. The report noted that the surge was driven by seven high value deals worth $2.6 billion, reflecting renewed investor confidence in scale and consolidation plays across pharma, biotech, and hospital segments. Bharat Biotech plans Rs 200–250 crore of capital expenditure in FY26 for a large vaccine manufacturing facility being developed under Sapigen Biologix Pvt Ltd in Bhubaneswar, Odisha, partly financed through debt raised from financial institutions.

Original title: “Bharat Biotech mulls IPO to raise over $500 million - India Tribune - Chicago”

This summary covers significant health news, including Generate Biomedicines' IPO, Aardvark Therapeutics pausing a drug trial, Sunway Healthcare's major IPO, Target's decision to remove synthetic colors from cereals, and Merck's layoffs. Other noteworthy events include EU's stance on abortion ... This summary covers significant health news, including Generate Biomedicines' IPO, Aardvark Therapeutics pausing a drug trial, Sunway Healthcare's major IPO, Target's decision to remove synthetic colors from cereals, and Merck's layoffs. Other noteworthy events include EU's stance on abortion access and the spread of bird flu in Pennsylvania. Aardvark Therapeutics paused its advanced-stage drug trial designed for a rare genetic disorder due to heart-related side effects, illustrating the company's caution in advancing treatment without proper safety assurances. Reflecting shifting consumer priorities and health sector changes, Target pledged to eliminate synthetic dyes from its cereals by May's end. Additionally, the EU announced utilizing a social fund to facilitate safe abortion access, marking a progressive stance on reproductive rights.

Original title: “Health News Highlights: IPOs, Trials, and Changes in Health Sector | Health”

Generate Biomedicines priced a $400M IPO at $16/share. Despite an asthma lead program, investors are watching the platform’s oncology reach. The IPO is a real-time signal about what public-market investors are currently willing to fund: platform narratives that claim to compress discovery timelines and generate multiple modalities, including assets relevant to cancer. At the same time, IPO coverage has highlighted a key diligence issue for AI-centric biotech valuations: industry observers still point out that a fully AI-discovered drug has not yet achieved U.S. Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under the ticker “GENB.” In February 2026, the offering was described as the largest biotechnology IPO to date for the year and part of an unusually active month for biotech listings. In addition to IPO proceeds, industry reporting cited more than $800 million in prior venture financing and approximately $110 million in collaboration payments from Amgen and Novartis tied to the company’s platform.

Original title: “Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus - OncoDaily”

Flagship Pioneering-founded Generate Biomedicines aims to offer less frequent injections compared to a blockbuster asthma drug from partners Amgen and AstraZeneca. Generate’s drug comes from a “programable biology” platform technology that uses AI and machine learning to design proteins ... Flagship Pioneering-founded Generate Biomedicines aims to offer less frequent injections compared to a blockbuster asthma drug from partners Amgen and AstraZeneca. Generate’s drug comes from a “programable biology” platform technology that uses AI and machine learning to design proteins with desirable properties. The most recent financing was a $273 million Series C round in 2023. Flagship holds a 48.76% post-IPO stake in Generate. Generate does record some revenue from ongoing R&D partnerships with Amgen and Novartis. As of the end of 2025, Generate reported its cash position was $221.5 million. Generate believes GB-0895 has potential applications in other respiratory conditions and a Phase 1b test is ongoing in moderate-to-severe chronic obstructive pulmonary disease. Data in this indication are expected later this year, according to the filing. The company’s technology has also yielded two cancer drugs, GB-4362 and GB-5267, both in early clinical development. Generate was founded in 2018 by Flagship Pioneering, a firm that builds startups around platform technologies. Since its inception and prior to the IPO, Generate had raised $805.3 million from selling equity in the company, according to the filing. Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could offer a dosing edge over blockbuster asthma medicines currently available, and the company now has $400 million in IPO cash to support two ongoing pivotal clinical trials.

Original title: “Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug - MedCity News”

Generate’s raise exceeds Eikon’s ... biotech. Prior to the IPO, Generate had secured nearly $700 million in private equity financing since its founding in 2018, including a $370 million Series B in 2021 and a $273 million Series C in 2023. The company has also signed large pharmaceutical partnerships, including ... Generate’s raise exceeds Eikon’s February 2026 $380 million IPO, placing it among the largest recent financings for a clinical-stage, AI-enabled biotech. Prior to the IPO, Generate had secured nearly $700 million in private equity financing since its founding in 2018, including a $370 million Series B in 2021 and a $273 million Series C in 2023. The company has also signed large pharmaceutical partnerships, including a collaboration with Amgen valued at up to $1.9 billion and a separate agreement with Novartis reportedly exceeding $1 billion, both focused on AI-designed protein therapeutics. Around $100 million will support a Phase Ib trial and further clinical development of the same antibody in chronic obstructive pulmonary disease with a separate phase 1 study. Remaining funds are designated for broader research and pipeline expansion.

Original title: “AI Protein Biotech Generate:Biomedicines Lands $400 IPO, Biggest in a While”

Four months after Avidity’s $11.4 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its predecessor’s work in cardiovascular disease.

Original title: “Atrium spins out of Avidity, aiming to target rare heart diseases with RNA”

Remarks the FDA commissioner made during a CNBC appearance seemed to stoke investor fears that UniQure's gene therapy for Huntington's won't get approved.

Original title: “UniQure falls further on Makary comments”

Generate Biomedicines Inc. raised proceeds of $400 million from its initial public offering, the largest biotech IPO Massachusetts has seen since 2020. Generate Biomedicines raised $400 million in its IPO, marking Massachusetts' largest life sciences offering since 2020 and signaling renewed momentum in biotech public markets. The Somerville company's success in the public markets could be a bellwether for other biotechs weighing whether to jump in after a period lacking in IPOs.

Original title: “Somerville biotech Generate Biomedicines IPO nets $400 million - Boston Business Journal”

The Flagship Pioneering company has completed the biggest initial public offering of 2026 so far, providing encouragement for more cash-hungry biotechs seeking a public listing.

Original title: “Generate’s $400m IPO Adds To Biotech Bounceback”